KDM4C抑制剂SD70与menin抑制剂MI-503对MLL::AF9驱动急性髓系白血病的协同作用
约10%的急性髓系白血病(AML)存在MLL重排且预后较差。本研究通过组合药物筛选发现,KDM4C抑制剂SD70与menin-MLL抑制剂MI-503联用可协同增强MLL::AF9白血病细胞凋亡而不影响正常CD34+细胞,并在AML异种移植模型中显著延长生存。RNA-seq显示MYC靶基因下调最显著,提示该组合是MLL::AF9 AML的潜在双靶向治疗。
要点
- SD70与MI-503联用协同增强MLL::AF9白血病细胞凋亡,不影响正常CD34+细胞。
- 体内SD70联合MI-503显著延长AML异种移植模型生存。
- 联合用药后RNA-seq显示MYC靶基因下调最显著。
核心结论
- SD70与MI-503联用是MLL::AF9 AML的潜在双靶向治疗,基于临床前证据。
研究设计与样本
- 采用组合药物筛选为KDM4C抑制剂SD70选择性寻找协同治疗伙伴,并在MLL::AF9白血病细胞、正常CD34+细胞及AML异种移植模型中评价。
主要发现
- SD70与MI-503联用协同增强MLL::AF9白血病细胞凋亡,而不影响正常CD34+细胞。
- 体内SD70联合MI-503治疗显著延长AML异种移植模型生存。
- 联合用药后RNA-seq差异基因表达分析显示众多基因变化,其中MYC靶基因下调最显著。
关键数值与推荐
- MLL重排白血病约占急性髓系白血病(AML)的10%,与相对较差预后相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
MLL-rearranged (MLL-r) leukaemia is observed in approximately 10% of acute myeloid leukaemia (AML) and is associated with a relatively poor prognosis, highlighting the need for new treatment regimens. MLL fusion proteins produced by MLL rearrangements recruit KDM4C to mediate epigenetic reprogramming, which is required for the maintenance of MLL-r leukaemia. In this study, we used a combinatorial drug screen to selectively identify synergistic treatment partners for the KDM4C inhibitor SD70. The results showed that the drug combination of SD70 and MI-503, a potent menin-MLL inhibitor, induced synergistically enhanced apoptosis in MLL::AF9 leukaemia cells without affecting normal CD34+ cells. In vivo treatment with SD70 and MI-503 significantly prolonged survival in AML xenograft models. Differential gene expression analysis by RNA-seq following combined pharmacological inhibition of SD70 and MI-503 revealed changes in numerous genes, with MYC target genes being the most significantly downregulated. Taken together, these data provide preclinical evidence that the combination of SD70 and MI-503 is a potential dual-targeted therapy for MLL::AF9 AML.
引用
- Zhu W, Ding Y, Huang W, et al. Synergistic effects of the KDM4C inhibitor SD70 and the menin inhibitor MI-503 against MLL::AF9-driven acute myeloid leukaemia. Br J Haematol. 2024. PMID: 38877874. doi:10.1111/bjh.19591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。